REXAHN PHARMACEUTICALS, INC.
Net BuyingRXHN·US·🇺🇸 US
85%buys·15%sales
489 transactions$2.9MTotal buys·72 buys
$19.9MTotal sells·13 sells
4444 insiders
Last: Dec 31, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Dec 31, 25 | Gallagher Cam | Grant | - | |
| Dec 29, 25 | Gallagher Cam | Buy | $164K | |
| Dec 29, 25 | Gallagher Cam | Buy | $160K | |
| Dec 9, 25 | Foundation Fighting Blindness, Inc. | Sell | $8.6M | |
| Dec 9, 25 | Foundation Fighting Blindness Retinal Degeneration Fund | Sell | $8.6M | |
| Nov 1, 25 | Magrath George | Other | $70K | |
| Nov 1, 25 | Magrath George | Other | $70K | |
| Oct 22, 25 | YERXA BENJAMIN R | Other | $46K | |
| Sep 10, 25 | Gagnon Robert E. | Grant | - | |
| Sep 2, 25 | Gagnon Robert E. | Grant | - |
REXAHN PHARMACEUTICALS, INC. (RXHN) has recorded 489 insider transactions from 44 insiders. Total insider buying volume stands at $2.9M, while total selling volume is $19.9M. Overall insider sentiment is bullish (85% purchases).
REXAHN PHARMACEUTICALS, INC. (RXHN) has recorded 489 insider operations, including 72 open-market purchases ($2.9M), 13 sales ($19.9M) and 404 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (85% purchases).
Insider activity at REXAHN PHARMACEUTICALS, INC. is sustained, with operations recorded in 10 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are Rodgers Richard J (CEO), Ahn Chang Ho (CEO) & Swirsky Douglas J (CEO), with respectively 96, 64, 63 transactions.
Across all 489 recorded transactions, the breakdown by type is: grant (307, 63%), buys (72, 15%), exercise (34, 7%), gift (32, 7%), disposition (18, 4%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
REXAHN PHARMACEUTICALS, INC. has recorded 489 insider operations in total, including 72 open-market purchases ($2.9M), 13 sales ($19.9M) and 404 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on December 31, 2025.
Insiders at REXAHN PHARMACEUTICALS, INC. are currently net buyers, with 85% purchases and 15% sales across all reported transactions. Total buy volume is $2.9M versus $19.9M in sales, indicating a bullish insider sentiment.
InsiderLens tracks 44 insiders at REXAHN PHARMACEUTICALS, INC. (RXHN). Rodgers Richard J (CEO, 96 tx), Ahn Chang Ho (CEO, 64 tx), Swirsky Douglas J (CEO, 63 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for RXHN is bullish, based on a 85% buy ratio across 85 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for REXAHN PHARMACEUTICALS, INC. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.